FibroGen’s stock skyrockets upon the positive results of a new study

By Catherine Sturman
Biotech company FibroGen stock has soared by over 50% upon the positive results of new lung disease drug pamrevlumab within clinical trials. Used to ta...

Biotech company FibroGen stock has soared by over 50% upon the positive results of new lung disease drug pamrevlumab within clinical trials.

Used to tackle lung disease idiopathic pulmonary fibrosis, the company has recently completed FDA tests, at which these positive results will provide significant revenue increases for the company, adding $3 to $4 billion to its market cap to “eventually $35 to $50 to its share price,” CNBC has reported.

Idiopathic pulmonary fibrosis leads to severe scarring on the lungs, which impacts on oxygen which can be transferred into a patient’s bloodstream. The disease leads to severe breathing problems and high mortality rates, with five years granted post prognosis.

Pamrevlumab has been described by FibroGen as a “monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). CTGF is a common factor in chronic fibrotic and proliferative disorders, characterized by persistent and excessive fibrous tissue which can lead to organ dysfunction and failure, and in cancer, by promotion of tumour growth.

Related stories

Pamrevlumab is used for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD).”

Completing Phase 2 will lead to the third phase in clinical trials, which could lead to potential breakthroughs in treatment. The trials saw participants take pamrevlumab or placebo for up to 48 weeks.

“We are very encouraged by the top line IPF Phase 2 clinical study results that we announced today, in which pamrevlumab-treated patients had a significantly lower rate of decline in lung function, as compared to the placebo-treated patients,” commented FibroGen CEO Thomas B. Neff. “In addition, pamrevlumab continued to be well tolerated as a monotherapy in this IPF study, and was well tolerated in combination with pirfenidone and nintedanib.

We believe that the promising outcomes of these studies enable us to advance pamrevlumab into Phase III clinical development.”

Share

Featured Articles

Hyfe AI uses acoustic AI in its digital cough monitoring

Hyfe uses acoustic AI in its digital cough monitoring. Dr. Joe Brew, Co-Founder & CEO of Hyfe AI, tells us more about coughing technology post-COVID-19

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Digital Healthcare

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma